Myelodysplastic Syndromes
July 2023 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment.
Authors:Bewersdorf JP, Xie Z, Zeidan AM
Institution:From the Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Journal:Cancer J. 2023 May-Jun 01;29(3):195-202. doi: 10.1097/PPO.0000000000000658.

2:Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in?
Authors:Abaza Y, Patel AA
Institution:From the Department of Hematology and Oncology, Northwestern University, Robert Lurie Cancer Center.; Section of Hematology/Oncology, Department of Medicine, University of Chicago, IL.
Journal:Cancer J. 2023 May-Jun 01;29(3):188-194. doi: 10.1097/PPO.0000000000000657.

3:Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions.
Authors:Sabile J, Pavletic S, Migdady Y
Institution:From the Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Journal:Cancer J. 2023 May-Jun 01;29(3):179-187. doi: 10.1097/PPO.0000000000000662.

4:Supportive Care for Patients With Myelodysplastic Syndromes.
Authors:Stempel JM, Podoltsev NA, Dosani T
Institution:
Journal:Cancer J. 2023 May-Jun 01;29(3):168-178. doi: 10.1097/PPO.0000000000000661.

5:Overview of the Management of Higher-Risk Myelodysplastic Syndromes.
Authors:Singh A, Carraway HE
Institution:From the Leukemia and Myeloid Disorder Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Journal:Cancer J. 2023 May-Jun 01;29(3):160-167. doi: 10.1097/PPO.0000000000000664.

6:The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.
Authors:Randall MP, DeZern AE
Institution:From the Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA.; Division of Hematologic Malignancies, The Johns Hopkins University School of Medicine, Baltimore, MD.
Journal:Cancer J. 2023 May-Jun 01;29(3):152-159. doi: 10.1097/PPO.0000000000000655.

7:Updates in Risk Stratification in Myelodysplastic Syndromes.
Authors:Aguirre LE, Sallman DA, Stone R, Komrokji RS
Institution:From the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Journal:Cancer J. 2023 May-Jun 01;29(3):138-142. doi: 10.1097/PPO.0000000000000654.

8:Updates in Classification of Myelodysplastic Syndrome.
Authors:Xu ML, Hasserjian RP
Institution:From the Yale University, New Haven, CT.; Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Journal:Cancer J. 2023 May-Jun 01;29(3):122-129. doi: 10.1097/PPO.0000000000000659.

9:Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
Authors:Rotter LK, Shimony S, Ling K, Chen E, Shallis RM, Zeidan AM, Stahl M
Institution:Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Journal:Cancer J. 2023 May-Jun 01;29(3):111-121. doi: 10.1097/PPO.0000000000000665.

10:An overview of myelodysplastic syndromes.
Authors:Pontrelli G, Loscalzo C, L'Eplattenier M
Institution:Gina Pontrelli, Carina Loscalzo , and Mark L'Eplattenier are assistant professors in the PA program at Hofstra University in Hempstead, N.Y. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Journal:JAAPA. 2023 Jun 1;36(6):17-21. doi: 10.1097/01.JAA.0000931428.87936.72.

11:Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Authors:Pophali P, Desai SR, Shastri A
Institution:Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Department of Oncology, Department of Developmental & Molecular Biology, Montefiore Medical Center & Albert Einstein College of Medicine, Chanin 302A, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. ashastri@montefiore.org.
Journal:Curr Hematol Malig Rep. 2023 Jun;18(3):56-67. doi: 10.1007/s11899-023-00693-9. Epub 2023 Apr 13.

12:Raising the bar for lower-risk myelodysplastic syndromes.
Authors:Venugopal S, Sekeres MA
Institution:Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Journal:Leuk Lymphoma. 2023 Jun;64(6):1082-1091. doi: 10.1080/10428194.2023.2197536. Epub 2023 Apr 8.

13:Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Authors:Wang C, Sallman DA
Institution:Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. David.Sallman@moffitt.org.
Journal:Curr Treat Options Oncol. 2023 May;24(5):387-408. doi: 10.1007/s11864-023-01062-7. Epub 2023 Mar 25.

14:Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Authors:Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG
Institution:Moffitt Cancer Center, Tampa, FL.; The University of Texas MD Anderson Cancer Center, Houston, TX.
Journal:J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8.

15:Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
Authors:Tinsley-Vance SM, Ali NA, Ball S, Aguirre LE, Jain AG, Hussaini MO, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman DA, Komrokji RS
Institution:Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Electronic address: sara.tinsley@moffitt.org.
Journal:Clin Lymphoma Myeloma Leuk. 2023 May;23(5):355-359. doi: 10.1016/j.clml.2023.01.007. Epub 2023 Jan 16.

16:A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation.
Authors:Rashidi A, Huselton EJ, Stefanski HE, DeFor TE, Shanley R, Choi J, DiPersio JF, Juckett M, Miller JS, Weisdorf DJ, Schroeder MA
Institution:Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota; Clinical Research Division, Fred Hutchinson Cancer Center and Division of Oncology, University of Washington, Seattle, Washington. Electronic address: arashidi@fredhutch.org.; Division of Oncology, Washington University School of Medicine in St Louis, St Louis, Missouri.
Journal:Transplant Cell Ther. 2023 May;29(5):328.e1-328.e6. doi: 10.1016/j.jtct.2023.02.010. Epub 2023 Feb 19.

17:Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.
Authors:Brunner AM
Institution:Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Journal:Curr Opin Hematol. 2023 Mar 1;30(2):38-44. doi: 10.1097/MOH.0000000000000749. Epub 2022 Dec 23.

18:Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world.
Authors:Rozema J, Graafsma J, Hoogendoorn M, Kibbelaar R, Veeger N, van Roon E
Institution:Unit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, Groningen, the Netherlands; Department of Clinical Pharmacy & Pharmacology, Medical Centre Leeuwarden, Henri Dunantweg 2, Leeuwarden, the Netherlands. Electronic address: hanne.rozema@rug.nl.
Journal:J Geriatr Oncol. 2023 Mar;14(2):101418. doi: 10.1016/j.jgo.2022.101418. Epub 2023 Jan 17.

19:Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.
Authors:Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, Ramos F, Romero R, Salido-Fiérrez E, Pedro C, Bargay J, Muñoz-Novas C, López R, Rafel M, Valcárcel D
Institution:Department of Hematology, Hospital Universitari Vall dHebron, Barcelona, Spain.
Journal:Leuk Lymphoma. 2023 Mar;64(3):679-690. doi: 10.1080/10428194.2022.2154604. Epub 2022 Dec 28.

20:Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
Authors:Wang C, Sallman DA
Institution:Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Journal:Leuk Lymphoma. 2023 Mar;64(3):511-524. doi: 10.1080/10428194.2022.2140287. Epub 2022 Nov 25.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 25% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 18, 2023
179 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $39.95
  • Less 25% Discount = - $10.00
  • Discounted Price = $29.95(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $26.60
  • Less 25% Discount = - $6.65
  • Discounted Price = $19.95

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 25% discount when you order your Guidebook by phone.

To receive your 25% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS441600693

Coupon Expires: October 24, 2023



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.